Astellas has announced further expansion into southern Europe through the establishment of Astellas Pharma in Slovenia.

The new subsidiary, Astellas Pharma South East Europe, will market and sell Astellas’ drugs and products. These include Omnic and OmnicOCAS, treatments for functional symptoms of benign prostatic hyperplasia.

The company will also market Vesicare for the treatment of overactive bladder, Protopic for the treatment of atopic dermatitis and the immunosuppressant Prograf/ Advagrafn.

The move follows the establishment of subsidiaries in Romania and Bulgaria in 2009.

Astellas South East Europe will manage the company’s business in Romania and Bulgaria, as well as Slovenia, Croatia, and some operations in Bosnia-Herzegovina.